MA49841A - Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine - Google Patents
Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitineInfo
- Publication number
- MA49841A MA49841A MA049841A MA49841A MA49841A MA 49841 A MA49841 A MA 49841A MA 049841 A MA049841 A MA 049841A MA 49841 A MA49841 A MA 49841A MA 49841 A MA49841 A MA 49841A
- Authority
- MA
- Morocco
- Prior art keywords
- ubiquitine
- protease inhibitors
- specific protease
- carboxamides used
- carboxamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544083P | 2017-08-11 | 2017-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49841A true MA49841A (fr) | 2020-06-17 |
Family
ID=63405399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049841A MA49841A (fr) | 2017-08-11 | 2018-08-09 | Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11524966B1 (fr) |
| EP (1) | EP3665169A1 (fr) |
| JP (1) | JP2020530469A (fr) |
| AR (1) | AR112468A1 (fr) |
| AU (1) | AU2018316254B2 (fr) |
| CA (1) | CA3072449A1 (fr) |
| MA (1) | MA49841A (fr) |
| TW (1) | TW201920157A (fr) |
| WO (1) | WO2019032863A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112468A1 (es) | 2017-08-11 | 2019-10-30 | Forma Therapeutics Inc | Carboxamidas como inhibidores de proteasa específicos de ubiquitina |
| CN112823037B (zh) | 2018-08-09 | 2023-12-19 | 瓦洛健康股份有限公司 | 抑制去泛素化酶usp25和usp28 |
| CA3108676A1 (fr) | 2018-08-09 | 2020-02-13 | David J. Guerin | Carboxamides en tant qu'inhibiteurs de protease specifiques de l'ubiquitine |
| CN111909181B (zh) * | 2019-05-09 | 2023-02-07 | 杭州普济远成生物医药科技有限公司 | 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用 |
| CN111943879A (zh) * | 2020-08-03 | 2020-11-17 | 南通大学 | 一种(3s,4r)3-氨基-4(甲氧基甲基)吡咯烷-1-甲酸叔丁酯及其合成方法 |
| WO2023208174A1 (fr) * | 2022-04-28 | 2023-11-02 | 杭州普济远成生物医药科技有限公司 | Inhibiteur de désubiquitinase et son utilisation |
| CN115974747A (zh) * | 2022-09-30 | 2023-04-18 | 上海北卡医药技术有限公司 | 一种3-(3-氯丙基)-4-氧代吡咯烷-1-羧酸乙酯的制备方法及用途 |
| WO2024114793A1 (fr) * | 2022-12-01 | 2024-06-06 | 杭州普济远成生物医药科技有限公司 | Forme saline et forme cristalline d'un inhibiteur de protéase spécifique de l'ubiquitination, leur procédé de préparation et leur utilisation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5550800A (en) | 1999-06-22 | 2001-01-09 | School Of Pharmacy, University Of London, The | Diagnosis and treatment of alzheimer's disease |
| US20050130974A1 (en) * | 2003-10-17 | 2005-06-16 | Rigel Pharmaceuticals, Inc. | Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| SE0403171D0 (sv) | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | New compounds |
| UY32443A (es) * | 2009-02-13 | 2010-09-30 | Sanofi Aventis | Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento. |
| WO2010099166A1 (fr) | 2009-02-27 | 2010-09-02 | Siga Technologies, Inc. | Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue |
| JP5852658B2 (ja) | 2010-09-24 | 2016-02-03 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| EP2938610A2 (fr) | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibiteurs du complexe usp1/uaf1 désubiquitinase et leurs utilisations |
| EP2948438A4 (fr) | 2013-01-23 | 2016-10-05 | Univ Chicago | Méthodes et compositions d'inhibition des protéines atox1 et ccs impliquées dans le transfert du cuivre |
| US10913753B2 (en) | 2016-02-12 | 2021-02-09 | Valo Early Discovery, Inc. | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors |
| CN109071561B (zh) | 2016-02-12 | 2022-01-14 | 福马治疗股份有限公司 | 用作泛素特异性蛋白酶抑制剂的噻吩并吡嗪甲酰胺 |
| AR112468A1 (es) | 2017-08-11 | 2019-10-30 | Forma Therapeutics Inc | Carboxamidas como inhibidores de proteasa específicos de ubiquitina |
-
2018
- 2018-08-09 AR ARP180102268 patent/AR112468A1/es unknown
- 2018-08-09 CA CA3072449A patent/CA3072449A1/fr active Pending
- 2018-08-09 EP EP18760137.2A patent/EP3665169A1/fr active Pending
- 2018-08-09 AU AU2018316254A patent/AU2018316254B2/en active Active
- 2018-08-09 US US16/637,692 patent/US11524966B1/en active Active
- 2018-08-09 TW TW107127893A patent/TW201920157A/zh unknown
- 2018-08-09 JP JP2020507569A patent/JP2020530469A/ja active Pending
- 2018-08-09 MA MA049841A patent/MA49841A/fr unknown
- 2018-08-09 WO PCT/US2018/046061 patent/WO2019032863A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3665169A1 (fr) | 2020-06-17 |
| AU2018316254A1 (en) | 2020-02-20 |
| AU2018316254B2 (en) | 2022-07-14 |
| WO2019032863A1 (fr) | 2019-02-14 |
| US11524966B1 (en) | 2022-12-13 |
| AR112468A1 (es) | 2019-10-30 |
| CA3072449A1 (fr) | 2019-02-14 |
| JP2020530469A (ja) | 2020-10-22 |
| TW201920157A (zh) | 2019-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA49566A (fr) | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques | |
| MA53275A (fr) | Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| IL282103A (en) | Furinones as ubiquitin-specific protease 1 inhibitors | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA42032A (fr) | Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac | |
| EP3386981A4 (fr) | Hétérocycles utiles en tant qu'agents anticancereux | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA41291A (fr) | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| EP3692028A4 (fr) | Inhibition de la peptidase 30 spécifique de l'ubiquitine | |
| EP3227425C0 (fr) | Compositions de nettoyage liquides comprenant des variantes de protéases | |
| EP3380200A4 (fr) | Compositions pour le traitement des cheveux | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
| EP3415146A4 (fr) | Inhibiteur de l'activation des inflammasomes | |
| EP3380063A4 (fr) | Compositions pour le traitement des cheveux | |
| MA50250A (fr) | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 | |
| EP3530722A4 (fr) | Composition d'agent nettoyant | |
| EP3512839A4 (fr) | Inhibiteurs de yap1 ciblant l'interaction de yap1 avec oct4 |